Scoping review identifies therapeutic targets and mechanisms of action involved in clinical trials for pulmonary fibrosis, suggesting new treatment paths.
This scoping review identifying and analyzing innovative pharmacological therapies in Phase II and III clinical trials for IPF. The study summarizes mechanisms of action, therapeutic targets, and molecular pathways involved in fibrogenesis, based on systematic database ClinicalTrials.gov.
No takes yet. Share an insight, caveat, or question.
Novara et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: